Intravitreal Faricimab in Diabetic Macular Edema With Limited Response to Aflibercept

Inclusion Criteria: * Male or female patients ≥ 18 years of age and documented diagnosis of diabetes mellitus (Type 1 or Type 2) * Patients with diagnosis of diabetic macular edema (DME). * Pre-treatment with intravitreal aflibercept in a treat and extend regimen and failing to be extended from the minimum interval of 4 weeks by two weeks to a 6-weeks interval without recurring DME activity or showing persisting DME activity in all visits under 4-weekly aflibercept treatment for at least 6 months. * Patients who have a Best corrected Visual Acuity (BCVA) of at least 20/160 (letter score 40 letters) in the study eye using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. * Willing and able to give written informed consent according to legal requirements, and who have signed the consent form prior to initiation of any study procedure including withdrawal from exclusionary medications for the purpose of this study. * Willing and able to comply with study procedures. * For women of childbearing potential: agreement to remain abstinent or use acceptable contraceptive methods that result in a failure rate of \<1% per year during the treatment period and for at least 3 months after the final dose of study treatment Exclusion Criteria: * Treatment with panretinal photocoagulation or macular laser within 3 months prior to Day 1 to the study eye * Any intraocular or periocular corticosteroid treatment within 6 months prior to Day 1 to the study eye * Prior administration of…